Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents

Coronary Artery Disease

Volumn 23, Issue 6, 2012, Pages 380-390

  Kar, Subrata ^a   Bhatt, Deepak L ^b  

^a University of Missouri   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndrome; atrial fibrillation; direct thrombin inhibitors; factor Xa inhibitors; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; PLACEBO; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; BRAIN HEMORRHAGE; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; DRUG BLOOD LEVEL; DRUG ELUTING STENT; DRUG HALF LIFE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; BENZIMIDAZOLES; BETA-ALANINE; DRUG THERAPY, COMBINATION; FACTOR XA; HEMORRHAGE; HEPARIN; HUMANS; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; THIOPHENES; TICLOPIDINE; WARFARIN;

EID: 84864829605     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328356490a     Document Type: Review

References (30)

1. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105:557-563. (Pubitemid 34123428)
2. Wang TY, Chen AY, Peterson ED, Becker RC, GiblerWB, Ohman EM, Roe MT. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 2008; 29:1103-1109. (Pubitemid 351844888)
3. Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, et al. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2012; 28:48-53.
4. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519-526.
5. Douketis JD. Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why? Thromb Res 2011; 127:513-517.
6. Depta JP, Cannon CP, Fonarow GC, Zhao X, PeacockWF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009; 104:1171-1178.
7. Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006; 105:80-85. (Pubitemid 43189779)
8. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572-584.
9. Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010; 104:657-663.
10. Davis EM, Packard KA, Knezevich JT, Campbell JA. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011; 31:975-1016.
11. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15-20.
12. Yong CM, Boyle AJ. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. Curr Vasc Pharmacol 2010; 8:5-11.
13. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl 2):S5-S12.
14. Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res 2011; 127:497-504.
15. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
16. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
17. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
18. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699-708.
19. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781-2789.
20. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012; 125:669-676.
21. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized Controlled Trials. Arch Intern Med 2012; 172:397-402.
22. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
23. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
24. Karthikeyan G, Eikelboom JW. Apixaban in acute coronary syndromes. Cardiovasc Ther 2011; 29:285-290.
25. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
26. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72:581-592.
27. Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res 2008; 123 (Suppl 1):S2-S6.
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-115.
29. Eikelboom JW,Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
30. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.